Significance of febrile episode in patients with lung cancer during therapy - comparison of NSCLC and SCLC patients Source: Eur Respir J 2002; 20: Suppl. 38, 356s Year: 2002
The incidence of neutropenia in patients undergoing outpatient chemotherapy for lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 755s Year: 2006
Risk factors of febrile neutropenia induced by chemotherapy in lung cancer patients Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016
Neutropenia in lung cancer cases after chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 753s Year: 2006
Survival of patients with relapsing small cell lung cancer (SCLC) after new line chemotherapy administration Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005
Lung cancer patients hospitalized for febrile neutropenia: A retrospective study Source: Annual Congress 2010 - Best supportive care and palliation for lung cancer patients Year: 2010
Assessment of lung cancer related symptoms and chemotherapy related side effects in a group of patients with advanced lung cancer receiving palliative chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 752s Year: 2006
Predictors of radiation-induced lung toxicity in patients with locally advanced non small cell lung cancer (NSCLC): a retrospective analysis Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009
Evaluation of outpatient infections in lung cancer patients treated with chemotherapy and/or radiotherapy Source: Annual Congress 2012 - Screening, diagnosis, staging and treatment strategies for lung cancer Year: 2012
Management of chemotherapy-induced anemia in patients with lung cancer (LC): A comparative study of erythropoietic agents Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
Second-line treatment patients at relapse of disseminated small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 395s Year: 2001
Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study Source: Eur Respir J, 52 (4) 1800884; 10.1183/13993003.00884-2018 Year: 2018
Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013
Chemotherapy for small cell lung cancer Source: Annual Congress 2006 - PG12 - Small cell lung cancer management Year: 2006
Pulmonary function during lung cancer therapy: A retrospective analysis of patients treated with monotherapy or multimodal treatments Source: International Congress 2016 – Clinical aspects of lung cancer Year: 2016
Docetaxel as second-line chemotherapy (CT) in advanced non small cell lung cancer(NSCLC) patients (pts): does it really work? Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003
Impact of radiotherapy on outcomes of nivolumab in advanced non-small cell lung cancer: a case controlled study Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018
Characteristics of lung cancer patients in Serbia and subsequent treatment in advanced NSCLC over time – epidemiology study Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017
Interstitial lung disease associated by gemcitabine chemotherapy in non-small lung cancer patients: Analysis based on the data in practical use with confirmed denominator Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases Year: 2011
Study of patient nominated symptoms and changing symptamatology in patients with lung cancer receiving palliative chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 323s Year: 2005